Real-World Nonhormonal Therapy Effects on VMS Bother, Work, and Mood
New data from the OPTION-VMS study shows that the nonhormonal therapy fezolinetant effectively reduces hot flashes and improves workplace productivity in menopausal women. The study also noted secondary improvements in anxiety and depression symptoms.
Why it matters
This research provides evidence for nonhormonal treatment options for menopause, which can significantly impact women's quality of life and professional performance.
Pauline M. Maki, PhD, reviews the first data cuts from OPTION-VMS, released at The Menopause Society 2025 meeting. These analyses examined bother from VMS, meaning hot flashes and night sweats, using the MENQOL, a commonly used measure of vasomotor symptom (VMS) bother, along with a widely used measure of workplace productivity.1
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in